Phenolic Glycolipid I confers advantage to *M. leprae* for invasion of the Peripheral Nerve System allowing modulation of Pattern Recognition Receptors and metabolism in Schwann cells favoring bacterial survival.

Chyntia Carolina Díaz Acosta<sup>1</sup>, Márcia de Berrêdo-Pinho<sup>1</sup>, André Alves Dias<sup>1</sup>, Thabatta Leal Silveira Andrezo Rosa<sup>1</sup>, Leonardo Ribeiro Batista Silva<sup>1</sup>, Thiago Gomes Toledo Pinto<sup>2</sup>, Fabrício da Mota Ramalho Costa<sup>1</sup>, Katherine Antunes de Mattos<sup>1,6</sup>, Luciana Rodrigues<sup>1,\*</sup>, Bruno de Siqueira Mietto<sup>2</sup>, Euzenir Nunes Sarno<sup>2</sup>, Patrícia Torres Bozza<sup>3</sup>, Christophe Guilhot<sup>4</sup>, Maria Cristina Vidal Pessolani<sup>1,\*</sup>

- 1. Laboratory of Cellular Microbiology, Oswaldo Cruz Institute, Rio de Janeiro, Brazil;
- 2. Leprosy Laboratory, Oswaldo Cruz Institute, Rio de Janeiro, Brazil.
- 3. Laboratory of Immunopharmacology, Oswaldo Cruz Institute, Rio de Janeiro, Brazil.
- 4. CNRS, IPBS (Institut de Pharmacologie et de Biologie Structurale), BP 64182, 31077 Toulouse, France

Present address: <sup>&</sup>Laboratory of Quality Control, Immunobiological Technology Institute, Bio-Manguinhos, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil. \*Medical Ciences Faculty, Rio de Janeiro State University, Brazil

Peripheral nerve damage is the more severe consequence of leprosy that occurs in all clinical forms of the disease. It results from the capacity of Mycobacterium leprae, an obligate intracellular bacillus, to infect Schwann cells (SC), the glial cells of the peripheral nervous system. These cells show remarkable plasticity and contribute to the regeneration capacity of the adult PNS even after severe injury. In-depth investigation aiming M. leprae-nerve interaction to develop new strategies for nerve impairment prevention and treatment is therefore of great importance. Previous studies have shown that M. leprae induces the production of insulin-like growth factor 1 favoring SC survival as well as drastic changes in SC lipid and glucose metabolism that promote bacterial persistence. Moreover, recent publications have shown the capacity of M. leprae to induce reprogramming of SC to a stage of progenitor/stemlike cells probably contributing to dissemination of infection. However the molecular mechanisms underlying these events and the contribution of M. leprae main glycolipid. such as PGL I, need to be better understood. Thus, to better decipher the role of this glycolipid in leprosy neuropathogenesis, besides M. leprae, a genetically engineered M. bovis BCG strain producing PGL I (BCG PGL I) was used as an alternative tool. In this work we have managed to show the critical role of PGL I on M. leprae adhesion and internalization in SC. We provide evidence that PGL I production and bacterial viability are determinants for mycobacterial internalization into SC. Furthermore, we propose that live PGL I producing mycobacteria modulate the expression of phagocytic receptors that specifically recognize cell wall envelope components expressed by pathogenic or slow growing mycobacteria. We demonstrate the engagement of CD206 that contributes to internalization and bacterial survival of live PGL I producing mycobacteria in SC. Additionally; we propose an active crosstalk between CD206 and the transcription factor PPARy modulating downstream immune functions in SC. PPARy is a member of the lipid-activated nuclear receptor family and has been demonstrated to function as a key transcriptional regulator in inflammation and lipid metabolism in macrophages and dendritic cells. We observed that the signaling pathway involving CD206 recognition followed by PPARy expression and activation lead to induction of IL-8 and prostaglandin E 2. In fact, while other proinflammatory cytokines may be reduced in anergic lepromatous patient, the host innate response involving the leucocyte attractant IL-8 seemed to be vigorous and could be involved in neuroinflammation.

**Keywords**: Peripheral nerve, Schwann cell modulation, *M. leprae*, Phenolic glycolipid I **Development Agency**: CAPES, CNPq, PEC-PG, IOC-FIOCRUZ